# A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06614192/  
OnCo record `nct06614192` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Telisotuzumab adizutecan in colorectal cancer, active and no longer recruiting.

## Summary

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06614192, led by AbbVie, and active but no longer recruiting on the registry. Official title: AndroMETa-CRC-064: An Open-Label, Randomised Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff. Planned enrolment is 74 participants (actual). The study started in 2024-11-08 and primary completion is expected in 2027-08. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: AndroMETa-CRC-064
- Tags: ctgov-ingest
- Registry id: NCT06614192
- Phase: 3
- Setting: AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
- Sponsor: AbbVie
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT06614192: https://clinicaltrials.gov/study/NCT06614192

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06614192.json